Literature DB >> 19390421

SALL4 is a novel diagnostic marker for testicular germ cell tumors.

Dengfeng Cao1, Jianping Li, Charles C Guo, Robert W Allan, Peter A Humphrey.   

Abstract

The diagnosis of testicular germ cell tumors (GCTs) sometimes can be challenging without ancillary markers. Here we performed an immunohistochemical study of a novel stem cell marker SALL4 in a large series of 110 primary testicular GCTs (65 pure and 45 mixed) containing the following types of tumors and/or tumor components: 50 intratubular germ cell neoplasias (ITGCNs), 62 classic seminomas, 2 spermatocytic seminomas, 39 embryonal carcinomas (EC), 5 pediatric and 26 postpubertal yolk sac tumors (YST), 7 pediatric and 25 postpubertal teratomas, and 5 choriocarcinomas. We compared SALL4 with OCT4 in all GCTs, and SALL4 to alpha-fetoprotein (AFP) and glypican-3 in all YSTs. To test SALL4 specificity, 23 testicular non-GCTs (10 Leydig cell tumors, 4 Sertoli cell tumors, 3 adenomatoid tumors, 3 paratesticular rhabdomyosarcomas, 2 diffuse large B-cell lymphomas, and 1 rete testis papillary cystadenoma) and 275 nontesticular tumors (158 metastatic carcinomas, 12 metastatic melanomas, 11 primary and 2 metastatic mesotheliomas, and 72 primary and 20 metastatic sarcomas) were also stained for SALL4. All ITGCNs, classic seminomas, and ECs demonstrated strong SALL4 and OCT4 staining in more than 90% tumor cells. All 31 YSTs (5 pediatric and 26 postpubertal) showed strong positive SALL4 staining in more than 90% tumor cells but had negative OCT4 staining. Both spermatocytic seminomas showed positive SALL4 staining in 80% to 95% tumor cells in all 3 types of tumor cells with weak-to-moderate staining intensity. Mononucleated trophoblastic cells were variably positive for SALL4 staining in all 5 choriocarcinomas. Focal SALL4 staining was seen in 4 of 7 pediatric and 23 of 27 postpubertal teratomas. OCT4 staining was not seen in any spermatocytic seminoma, choriocarcinoma, or teratoma. No SALL4 staining was seen in all 23 testicular non-GCTs. Of 275 nontesticular tumors, only 10 carcinomas and 1 sarcoma showed focal (<25% tumor cells) weak SALL4 staining. The only non-neoplastic cells within the testis stained with SALL4 were spermatogonia and few primary spermatocytes. AFP staining was seen in 29 of 31 YST but it was often focal and patchy. Although all 31 YSTs showed glypican-3 staining, 14 (45%) show staining in less than 30% tumor cells. Our findings indicate that SALL4 is a novel sensitive and relatively specific marker for testicular GCTs. SALL4 is a more sensitive marker than AFP and glypican-3 for YST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390421     DOI: 10.1097/PAS.0b013e3181a13eef

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  44 in total

Review 1.  Cervical lymph node metastases from remote primary tumor sites.

Authors:  Fernando López; Juan P Rodrigo; Carl E Silver; Missak Haigentz; Justin A Bishop; Primož Strojan; Dana M Hartl; Patrick J Bradley; William M Mendenhall; Carlos Suárez; Robert P Takes; Marc Hamoir; K Thomas Robbins; Ashok R Shaha; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-12-29       Impact factor: 3.147

Review 2.  [Spermatocytic seminoma. A tumor with many faces].

Authors:  G Mikuz
Journal:  Pathologe       Date:  2014-05       Impact factor: 1.011

3.  RNA-binding protein LIN28 is a sensitive marker of pediatric yolk sac tumors.

Authors:  Shaoguang Feng; Songsong Huang; Yulong Tong; Zhongliang Chen; Delei Shen; Dazhou Wu; Xin-He Lai; Xiaoming Chen
Journal:  Pediatr Surg Int       Date:  2016-06-29       Impact factor: 1.827

4.  ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.

Authors:  Guang-Qian Xiao; Faqian Li; Pamela D Unger; Hani Katerji; Qi Yang; Loralee McMahon; David E Burstein
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

5.  Teratoma of the Sellar Region: a Case Report.

Authors:  Wolfgang Saeger; Azadeh Ebrahimi; Rudi Beschorner; Hildegard Spital; Jürgen Honegger; Waldemar Wilczak
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

6.  SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases.

Authors:  Markku Miettinen; Zengfeng Wang; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Wojciech Biernat; Jerzy Lasota; Yi-Shan Lee
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

7.  SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

8.  SALL4 is a useful marker in the diagnostic work-up of germ cell tumors in extra-testicular locations.

Authors:  Philippe Camparo; Eva Maria Comperat
Journal:  Virchows Arch       Date:  2012-12-09       Impact factor: 4.064

9.  Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target.

Authors:  Shikiko Ueno; Jiayun Lu; Jie He; Ailing Li; Xiaoxian Zhang; Jerome Ritz; Leslie E Silberstein; Li Chai
Journal:  Exp Hematol       Date:  2014-01-23       Impact factor: 3.084

Review 10.  Functional and clinical significance of SALL4 in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik
Journal:  Tumour Biol       Date:  2016-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.